Overview

Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin

Status:
Completed

Trial end date:
2017-05-26

Target enrollment:

Participant gender:

Summary

This is a phase 1, open label, single-dose, crossover study to investigate the pharmacokinetics of YHP1604 in comparison to the co-administration of telmisartan/amlodipine and rosuvastatin in healthy male volunteers Hypothesis: "YHP1604" and "telmisartan/amlodipine and rosuvastatin" are showing equal pharmacokinetics.

Phase:

Phase 1

Details

Lead Sponsor:

Yuhan Corporation

Treatments:

Amlodipine
Rosuvastatin Calcium
Telmisartan